Acquiring Company
Temple
Acquired Company
Longévous
Greater LondonentertainmentBiotechnologyHealth CareMedicalDescription
Temple has acquired London-based Longévous, strengthening its clinical and scientific capabilities ahead of its product launch. Founders Dr. Robert Mohr and Dr. Avi Roy will join Temple’s leadership team in key roles. The acquisition is part of Temple's strategy to enhance its expertise in longevity medicine and provide better services to clients.
Don't miss Temple's next move
Get an email the moment Temple makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Longévous?
Longévous was acquired by Temple. The deal was reported on August 27, 2026. Temple is privately held and operates in entertainment.
When did Temple acquire Longévous?
Temple's acquisition of Longévous was reported on August 27, 2026. Temple has acquired London-based Longévous, strengthening its clinical and scientific capabilities ahead of its product launch. Founders Dr. Robert Mohr and Dr. Avi Roy will join Temple’s leadership team in key roles. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Longévous do?
Longévous is an evidence-based longevity medicine practice based in London. The founders, Dr. Robert Mohr and Dr. Avi Roy, bring extensive clinical and scientific expertise to the company. It is privately held, operating in Biotechnology, and is based in Greater London.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.